Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-160355
- form_type
- 8-K
- ticker
- TRVI
- cik
- 0001563880
- company_name
- Trevi Therapeutics, Inc.
- filed_at
- 2026-04-17T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.475031+00:00
- generated_at
- 2026-05-15T05:31:21.332589+00:00
- sec_items
- ["1.01", "2.02", "8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-160355
- json_url
- https://secwatch.observer/filing/0001193125-26-160355.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-160355.md
- text_url
- https://secwatch.observer/filing/0001193125-26-160355.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/0001193125-26-160355-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1563880/000119312526160355/d587027d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GPCR
Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials
Structure Therapeutics Inc.
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 2.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 2.02, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.
Filing page
SEC filing
KRMN
Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds
Karman Holdings Inc.
June 1, 2026, 5:28 PM ET
other_material
Items 1.01, 7.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).
Filing page
SEC filing
DGAC
Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE
DISCIPLINED GROWTH ACQUISITION Corp
June 1, 2026, 4:15 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent
Filing page
SEC filing
SAGU
Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE
Shreya Acquisition Group
May 11, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference
Filing page
SEC filing
CLRB
Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data
Cellectar Biosciences, Inc.
May 8, 2026, 7:59 PM ET
other_material
Items 1.01, 3.02, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”
Filing page
SEC filing
ETR
Entergy sells 19.2M shares via forward sale at $110.74, raising ~$2.13B
ENTERGY CORP /DE/
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
In connection with the Forward Sale Agreements, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC, Citigroup Global Markets Inc., Barclays Capital Inc. and Scotia Capital (USA) Inc., as the representatives of the underwriters named therein (the “Underwriters”), and Wells Fargo Securities, LLC, Citigroup Global Markets Inc., Barclays Capital Inc. and Scotia Capital (USA) Inc. as forward sellers (the “Forward Sellers”), pursuant to which the Forward Sellers sold to the Underwriters an aggregate of 19,247,788 shares of Common Stock.
Filing page
SEC filing
INGM
Principal stockholder launches $330M secondary offering; company to repurchase $30M of shares
Ingram Micro Holding Corp
May 7, 2026, 7:59 PM ET
other_material
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 8.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
On May 5, 2026, Ingram Micro Holding Company (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Ingram Holdco, LLC (the “Selling Stockholder”), Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC (collectively, the “Underwriting Representatives”) on their own behalf and as representatives of the other underwriters listed on Schedule I thereto (collectively, the “Underwriters”), pursuant to which the Selling Stockholder agreed to sell to the Underwriters, and the Underwriters agreed to purchase from the Selling Stockholder, subject to and upon the terms and conditions set forth therein, an aggregate of 12,740,384 shares (the “Shares”) of common stock, par value $0.01 per share of the Company (“Common Stock” and such sale and purchase, the “Offering”).
Filing page
SEC filing
USAR
USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity
USA Rare Earth, Inc.
June 2, 2026, 9:14 AM ET
other_material
Items 1.01, 2.03, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: other_material
similar materiality
This filing
On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).
Comparable filing
On June 1, 2026, USA Rare Earth, Inc. (the “Company”) entered into a Lease Agreement (the “Lease”) with TC Liberty Development, LLC, a Delaware limited liability company (“Landlord”), for the lease of a to-be-constructed specialty rare earth magnet manufacturing facility located on Bear Den Road in Blacksburg, Cherokee County, South Carolina (the “Premises”).
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.